What is Brief History of AngioDynamics Company?

AngioDynamics Bundle

Get Full Bundle:

	BCG	$15	$10
	5 FORCES	$15	$10
	CANVAS	$15	$10
	4P's MIX	$15	$10
	PESTLE	$15	$10
	SWOT	$15	$10

TOTAL:

ADD TO CART

What is the history of AngioDynamics?

AngioDynamics is a key innovator in medical technology, focusing on minimally invasive solutions. Its journey began in 1988 as a division of E-Z-EM, aiming to equip interventional radiologists with advanced tools.

The company has grown significantly, establishing itself as a leader in medical devices for peripheral vascular disease, oncology, and more. Its commitment to innovation is evident in products like the Auryon Atherectomy System, launched in 2020.

Discover the evolution of AngioDynamics, from its early days to its current standing as a major medical device provider. Learn about its strategic milestones and product advancements, including its role in peripheral artery disease treatment, which is detailed in the AngioDynamics BCG Matrix.

In fiscal year 2025, AngioDynamics achieved net sales of $292.5 million, showcasing substantial growth and market presence.

The AngioDynamics company's journey began on February 9, 1988, as a dedicated research and development arm of E-Z-EM. This venture was spearheaded by Eamonn P. Hobbs and Howard S. Stern, establishing its roots in Queensbury, New York. Stern, a co-founder of E-Z-EM in 1959, partnered with Hobbs, whose expertise in medical plastics was crucial for the new enterprise.

The Genesis of AngioDynamics

The AngioDynamics history is rooted in a strategic decision to expand E-Z-EM's business beyond its core barium sulfate products. The vision was to tap into the rapidly growing field of interventional radiology, focusing on innovative medical plastics for minimally invasive procedures. This marked a significant step in the AngioDynamics evolution.

• Founding Date: February 9, 1988
• Co-Founders: Eamonn P. Hobbs and Howard S. Stern
• Initial Focus: Medical plastics for interventional radiology
• Early Products: ProInfusion Catheter, Schon Acute Hemodialysis Catheter, Uni-Fuse Infusion Catheter

The AngioDynamics founding was driven by a clear market need: to diversify E-Z-EM's offerings and capitalize on the emerging interventional radiology sector. Eamonn P. Hobbs, with his specialized knowledge in medical plastics, was instrumental in guiding this new initiative. The company's initial business model was centered on developing advanced medical plastics designed for minimally invasive procedures, a key aspect of the Marketing Strategy of AngioDynamics.

The AngioDynamics company introduced its first products under its own name in 1991. These early innovations included the ProInfusion Catheter, which was part of the company's PulseSpray Sets. Other significant early developments were the Schon Acute Hemodialysis Catheter and the Uni-Fuse Infusion Catheter. The AngioDynamics early years and development presented challenges, particularly with longer-than-anticipated regulatory approval processes for these groundbreaking products, which necessitated the team to 'scramble to make ends meet' during this critical establishment phase.

AngioDynamics SWOT Analysis

• Complete SWOT Breakdown
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

The AngioDynamics company's early years were marked by rapid expansion and a strategic focus on developing innovative medical devices. From its beginnings as a division of E-Z-EM, the company quickly established a strong market presence in diagnostic catheters.

Founding and Initial Product Launch

Formally incorporated as A.D., Inc. in 1992, the company began shipping products in the early 1990s. Its first major product line, the SOFT VU Angiographic Catheters, was launched in 1992, setting the stage for future growth. By 1996, the company officially became AngioDynamics, Inc., with Eamonn P. Hobbs as President and CEO.

Product Innovation in the Late 1990s

The late 1990s saw a surge in product development, including the ANGIOPTIC and OMNIFLUSH Angiographic Catheters and the PulseSpray Injector in 1997. The following year, the Schon Acute Hemodialysis Catheter and UNIFUSE Infusion Catheter were introduced, further diversifying the company's offerings.

Transition to Public Company and Early 2000s Growth

The early 2000s brought innovations like Micro Access Sets and Image-Guided Vascular Access Products. A significant milestone was achieved in May 2004 when AngioDynamics became a publicly traded entity on the NASDAQ under the ticker ANGO. This period saw substantial financial growth, with sales reaching over $49 million in fiscal year 2004.

Strategic Acquisitions and Market Expansion

Strategic acquisitions played a crucial role in AngioDynamics' expansion. The acquisition of RITA Medical Systems in January 2007 marked the company's entry into oncology with thermal ablation technologies. This was followed by the acquisition of Oncobionic in May 2008, bringing the NanoKnife System into its portfolio. In May 2012, the acquisition of Navilyst Medical significantly boosted its presence in the vascular access market. Understanding the Revenue Streams & Business Model of AngioDynamics provides further insight into its growth strategy.

AngioDynamics PESTLE Analysis

• Covers All 6 PESTLE Categories
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

The AngioDynamics company has a rich history marked by significant milestones and technological advancements, alongside navigating various business challenges. This overview delves into the AngioDynamics overview, highlighting key developments in its journey.

AngioDynamics has consistently pushed the boundaries of medical technology with its innovative product lines. The NanoKnife System, a key component of its oncology offerings, represents a significant advancement in soft tissue ablation. Similarly, the Auryon Atherectomy System has revolutionized the treatment of Peripheral Artery Disease, with ongoing developments like the Auryon XL Catheter expanding its utility.

NanoKnife System (IRE Technology)

The NanoKnife System utilizes Irreversible Electroporation (IRE) for soft tissue ablation, a technology that has seen progressive regulatory approvals for various cancer treatments, including prostate tissue ablation. In Q3 FY2025, total NanoKnife sales reached $6.3 million.

Auryon Atherectomy System

Designed for Peripheral Artery Disease (PAD), the Auryon system, along with its XL Catheter, demonstrated strong market performance. In Q4 FY2025, Auryon sales grew by 19.7% to $15.6 million.

AlphaVac Mechanical Thrombectomy System

The AlphaVac system, part of the Mechanical Thrombectomy portfolio, received clearance for pulmonary embolism treatment. This segment, including AngioVac and AlphaVac, saw a substantial revenue increase of 44.7% to $11.3 million in Q4 FY2025.

The AngioDynamics company has encountered several challenges that necessitated strategic adjustments to its business model. These include significant divestitures of non-core assets and the discontinuation of certain product lines to streamline operations. Additionally, external factors like tariffs have impacted financial performance, leading to a strategic shift towards an outsourced manufacturing model.

Portfolio Streamlining

Strategic divestitures, such as the sale of its Dialysis and BioSentry businesses in June 2023 and its PICC and Midline product portfolios in February 2024, aimed to simplify the company's structure.

Product Line Adjustments

The discontinuation of RadioFrequency and Syntrax support catheter products in February 2024 was another step in focusing on core growth areas.

Financial and Operational Impacts

A $1.6 million tariff-driven cost impacted gross margin in Q4 FY2025, prompting a strategic pivot to an outsourced manufacturing model by Q3 FY2026.

AngioDynamics Business Model Canvas

• Complete 9-Block Business Model Canvas
• Effortlessly Communicate Your Business Strategy
• Investor-Ready BMC Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

The AngioDynamics company's journey began in 1988 as a division of E-Z-EM, later incorporating as A.D., Inc. in 1992. By 1996, it officially became AngioDynamics, Inc., marking a significant step in its AngioDynamics history. The company's evolution accelerated with its spin-off from E-Z-EM and public listing on NASDAQ in 2004, followed by strategic acquisitions that expanded its market presence and product offerings, shaping its AngioDynamics overview.

Strategic Growth and Expansion

The company is focused on executing its growth strategy by investing in high-growth Med Tech platforms. This includes expanding its global reach with new product launches and building upon its Mission, Vision & Core Values of AngioDynamics.

Financial Projections for FY2026

For fiscal year 2026, net sales are anticipated to be between $305 million and $310 million, a growth of 4% to 6% over FY2025's $292.5 million. Med Tech net sales are projected to grow by 12% to 15%.

Market Opportunity and Clinical Evidence

The company's portfolio addresses approximately $10 billion in annual global market opportunities. AngioDynamics is committed to generating definitive clinical evidence, as shown by the enrollment of the first patient in the AMBITION BTK trial in July 2025.

Future Outlook and Operational Goals

The company is positioned for sustained value creation into fiscal year 2026, aiming for positive free cash flow and a strong gross margin. This reinforces its founding vision of delivering high-quality medical solutions to improve patient outcomes.

AngioDynamics Porter's Five Forces Analysis

• Covers All 5 Competitive Forces in Detail
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔